The 14th Annual Summit of China Investment Conference, sponsored by CVINFO and CV Network and hosted by CV Capital, was held in Shanghai from June 10 to 12, 2020. This summit is also the largest offline summit in the investment community since the stabilization of the epidemic .

During the submit, one of the most important lists of the year in the venture capital industry was also released. Far Wing Investment, a venture capital fund initiated by Far East Horizon, was among the VC's core lists with its excellent results since 2019 and was also one of the youngest investment institutions in the list.

Far Wing Investment

Won

"2019 Best Venture Capital Institution"

Far Wing Investment

Aqara

Won

“Best New Consumption Investment Case”

Far Wing Investment

Peijia Medical

Won

"Best Medical Device Investment Case"

As an important section in the "China Investment Annual Meeting", the "CV List" has become a barometeFar Wing Investment

Won

"2019 Best Venture Capital Institution"

Far Wing Investment

Aqara

Won

“Best New Consumption Investment Case”

Far Wing Investment

Peijia Medical

Won

"Best Medical Device Investment Case"

r of the industry. After 13 years of professional research and market tracking, the selection of the "CV List" has become an annual event in China's private equity industry and has been widely supported and recognized by investment institutions, LP and practitioners.

In this year's selection, CV Research Institute focused on market-oriented investment institutions in China and set up five evaluation criteria, including the scale of raised funds, the number and scale of investment cases, the number and scale of withdrawal cases, performance and projects under management from January 1, 2019 to December 31, 2019. A combination of quantitative and qualitative methods was adopted for the selection. Finally, qualified Chinese equity investment institutions were selected according to the scores to enter the main list, sub-list, service organization list and industrial investment sub-list.

China has entered a post-epidemic era. With the resumption of work and production, the deadlock in VC/PE market has gradually broken, and the offering and investment markets have bottomed out and rebounded. According to CVSource investment data, VC/PE investment saw a sharp rise of 82% in the number of transactions as compared with February, when the epidemic was most serious. Although it is still difficult for institutions to raise funds and investment remains cautious, the rebound in the market is gratifying.

The Far Wing Investment has not stood still against the background of the epidemic.

It has successively made investments in nearly 10 projects in the past six months, with an investment amount of nearly RMB 1 billion. It has also recieved significant gains in withdrawing from the market. It has completed nearly 20% of the cash return of the first phase of the fund in half a year, and also completed the Hong Kong IPO of Peijia Medical that belongs to the second phase of the bulk-holding fund, making the IRR of the second phase of the fund exceed three digits.

As for fund-raising, Far Wing Investment has performed excellently, which is recognized by more and more professional LP. The second phase of RMB fund of Far Wing Investment will soon complete its final closing, with an estimated scale of RMB 2 billion.

Far Wing Investment will definitely live up to its mission, deliver better results to investors and make due contributions to the industry.